This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While not a panacea, these technologies can be part of a comprehensive set of solutions that help close the gap of inequity in medicine and drug development.
Companies are testing the use of digital platforms along with pharmacological treatments. But while appealing, the prospects of developing a merged approach that combines both digital and pharmacological therapeutics remain challenging. Digital therapeutics can be also categorised based on their regulatory journey.
Cala , the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease.
Typically, a drug label refers to any information provided with prescription drugs, as requested by regulators such as the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA).
We have programmes that investigate the types of medicines we produce and how we produce them, the energy we use (globally, 99 percent of our energy comes from renewable sources), and the practices of our entire global value chain. Pulmonary Pharmacology & Therapeutics. He has previously held positions at GSK and Sanofi.
They must be familiar with the different national authorities; the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulations that govern the pharmaceutical marketing and sales. This knowledge can include pharmacology, therapeutic areas, and data from clinical trials with different medications.
Regulation changes, like the introduction of the Prescription Drug Marketing Act in the 1980s, brought about a more structured approach. Another game-changer has been the shift towards personalized medicine. Personalized medicine is on the rise, opening doors for reps who can combine deep product knowledge with a personalized approach.
On the one hand, patient need for access and business need to restore and accelerate sales and prescription momentum have never been more critical. Having a flawless technical grasp of the medicine is no longer sufficient. On the other hand, HCP access for the field force has never been more challenging.
6 Therefore, the quality of data provided to regulators will be key in obtaining MAs and subsequently marketing of psychedelic medicines. 6 Therefore, the quality of data provided to regulators will be key in obtaining MAs and subsequently marketing of psychedelic medicines.
You want to use it to show what is working well, or tell ‘if you’re struggling in this situation, I want to identify the trigger,’” says Dr. Jose Castillo-Mancilla, associate professor, School of Medicine, University of Colorado, Anschutz. But the pharmacology to quantify adherence also depends on race, gender, weight, and other factors.
1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. 2 Approach taken by regulators in the UK The Medicines and Healthcare products Regulatory Agency regulates herbal medicines in the UK. 2012/1916). 2012/1916). 2012/1916).
To say two is fine and enough does a disservice to women,” states Sheryl Kingsberg, PhD, Chief of the Division of Behavioral Medicine at the University Hospitals Cleveland. All this development comes in the backdrop of a wider sense of stigma against the use of pharmacologic options for female sexual function, says Kingsberg.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content